Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-19T21:38:03.227Z Has data issue: false hasContentIssue false

Are SSRIs a Cost-Effective Alternative to Tricyclics?

Published online by Cambridge University Press:  02 January 2018

Matthew Hotopf*
Affiliation:
Department of Psychological Medicine, King's College School of Medicine and Dentistry, and Institute of Psychiatry
Glyn Lewis
Affiliation:
Epidemiology Unit, London School of Hygiene and Tropical Medicine, and Section of Epidemiology and General Practice, Institute of Psychiatry
Charles Normand
Affiliation:
Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London WC1E 7HT
*
Dr Hotopf, Institute of Psychiatry, 103 Denmark Hill, London SE5 8AF

Abstract

Background

Selective serotonin reuptake inhibitors (SSRIs) are more expensive than tricyclics. Reports have suggested that SSRIs are cost-effective because they are better tolerated and safer in overdose.

Method

A systematic review of all randomised controlled trials (RCTs), meta-analyses, and cost-effectiveness studies comparing SSRIs and tricyclic antidepressants (TCAs).

Results

None of the RCTs provided an economic analysis and there were methodological problems in the majority which would preclude this approach. Meta-analyses suggest that clinical efficacy is equivalent but slightly fewer patients prescribed SSRIs drop out of RCTs. Cost-effectiveness studies have been based on crude ‘modelling’ approaches and over-estimate the difference in attrition rates and the cost of treatment failure. It appears impossible to evaluate the economic aspects of suicide because of its rarity.

Conclusions

There is no evidence to suggest that SSRIs are more cost-effective than TCAs. The debate will only be concluded when a prospective cost-effectiveness study is done in the setting of a large primary care based RCT.

Type
Review Article
Copyright
Copyright © Royal College of Psychiatrists, 1996 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alvarez, F. & Del Rio, M. (1994) Drugs and driving. Lancet, 344, 282.CrossRefGoogle ScholarPubMed
Anderson, I. M. & Tomenson, B. M. (1995) Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. British Medical Journal, 310, 14331438.CrossRefGoogle ScholarPubMed
Ashford, J. J. (1994) Total profile of drug should be considered. British Medical Journal, 309, 1083.Google ScholarPubMed
Beuzen, J. N., Ravily, V. F., Souetre, E. J., et al (1993) Impact of fluoxetine on work loss in depression. International Journal of Psychopharmacology, 8, 319321.CrossRefGoogle ScholarPubMed
Blacker, C. V. R. & Clare, A. W. (1987) Depressive disorder in primary care. British Journal of Psychiatry, 150, 737751.CrossRefGoogle ScholarPubMed
Boyer, W. F. & Feighner, J. P. (1993) The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naïve depressed patients. In Health Economics of Depression (eds Jönsson, B. & Rosenbaum, J.), pp. 6575. London: Wiley.Google Scholar
Bratfos, O. & Haug, J. O. (1968) The course of manic-depressive psychosis: a follow-up investigation of 215 patients. Acta Psychiatrica Scandinavica, 44, 89112.CrossRefGoogle ScholarPubMed
Carr-Hill, R. A. (1991) Current practice in obtaining the “Q” in QALYs: a cautionary note. British Medical Journal, 305, 699701.CrossRefGoogle Scholar
Croft-Jeffreys, C. & Wilkinson, G. (1989) Estimated costs of neurotic disorder in UK general practice 1985. Psychological Medicine, 19, 549558.CrossRefGoogle ScholarPubMed
Donovan, S., McGrady, H., Pownall, R., et al (1993) The efficacy and tolerability of dothiepin and three selective serotonin reuptake inhibitors in the treatment of major depression: a review of six double blind studies. Current Therapeutic Research, 54, 275289.CrossRefGoogle Scholar
Drugs and Therapeutic Bulletin (Anon) (1993) Selective serotonin reuptake inhibitors for depression. Drugs and Therapeutic Bulletin, 31, 5758.CrossRefGoogle Scholar
Drummond, M. F., Stoddard, G. L. & Torrance, G. W. (1987) Methods for the Economic Evaluation of Health Care. Oxford: Oxford University Press.Google Scholar
Edwards, G. (1995) Suicide and antidepressants. British Medical Journal, 310, 205206.CrossRefGoogle ScholarPubMed
Effective Health Care (1993) The treatment of depression in primary care. Effective Health Care Bulletin, 5, 112.Google Scholar
Freemantle, N., House, A., Song, F., et al (1994) Prescribing selective serotonin reuptake inhibitors as a strategy for prevention of suicide. British Medical Journal, 309, 249253.CrossRefGoogle Scholar
Freemantle, N. & Maynard, A. (1994) Something rotten in the state of clinical and economic evaluations. Health Economics, 3, 6367.CrossRefGoogle ScholarPubMed
Goldacre, M., Seagroatt, V. & Hawton, K. (1993) Suicide after discharge from psychiatric in-patient care. Lancet, 342, 283286.CrossRefGoogle Scholar
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 5662.CrossRefGoogle ScholarPubMed
Henry, J. A. & Martin, A. J. (1987) The risk-benefit assessment of antidepressant drugs. Medical Toxicology, 21, 445462.CrossRefGoogle Scholar
Jônsson, B. (1994) Economic evaluation and clinical uncertainty: response to Freemantle and Maynard. Health Economics, 3, 305307.CrossRefGoogle ScholarPubMed
Jônsson, B. & Bebbington, P. E. (1994) What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. British Journal of Psychiatry, 164, 665673.CrossRefGoogle ScholarPubMed
Kind, P. & Sorensen, J. (1993) The costs of depression. International Journal of Psychopharmacology, 7, 191195.CrossRefGoogle ScholarPubMed
Le Pen, C., Levy, E., Ravily, V., et al (1994) The cost of treatment dropout in depression. A cost benefit analysis of fluoxetine vs tricyclics. Journal of Affective Disorders, 31, 118.CrossRefGoogle ScholarPubMed
Montgomery, S. A., Henry, J., McDonald, G., et al (1994) Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. International Clinical Psychopharmacology, 9, 4753.CrossRefGoogle ScholarPubMed
Montgomery, S. A., Kasper, S. (1995) Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. International Clinical Psychopharmacology, 9 (suppl 4), 3340.CrossRefGoogle ScholarPubMed
Office of Population Censuses and Surveys (1990) Mortality Statistics. London: HMSO.Google Scholar
Pande, A. C. & Sayler, M. E. (1993) Adverse events and treatment discontinuations in fluoxetine clinical trials. International Clinical Psychopharmacology, 8, 267269.CrossRefGoogle ScholarPubMed
Paykel, E. S. (1989) The background: extent and nature of the disorder. In Depression: an Integrative Approach (eds Herbst, K. & Paykel, E. S.), pp. 317. Oxford: Heinemann.Google Scholar
Paykel, E. S. Priest, R. G. (1992) Recognition and management of depression in general practice: consensus statement. British Medical Journal, 305, 11981202.CrossRefGoogle ScholarPubMed
Perris, C. & D'Elia, G. (1966) A study of bipolar and unipolar depressive psychoses: mortality, suicide and life cycles. Acta Psychiatrica Scandinavica, 194 (suppl), 172183.CrossRefGoogle ScholarPubMed
Song, F., Freemantle, N., Sheldon, T. A., et al (1993) Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. British Medical Journal, 306, 683687.CrossRefGoogle ScholarPubMed
Tubman, T. R. J., Halliday, H. L. & Normand, C. (1990) Cost of surfactant treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial. British Medical Journal, 301, 842845.CrossRefGoogle ScholarPubMed
van Howvelingen, H. C. & Zwinderman, K. H. (1993) A bivariate approach to meta-analysis. Statistics in Medicine, 12, 22732284.CrossRefGoogle Scholar
Wells, K. B., Stewart, A., Hays, R. D., et al (1989) The functioning and wellbeing of depressed patients: results from the medical outcomes study. Journal of the American Medical Association, 262, 914919.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.